Angiogenesis Inhibitors
1 clinical trials · Condition
◉ Watch Angiogenesis Inhibitors
| Record | Firm | Date |
|---|---|---|
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer (NCT06134193) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2023-11-01 |
Track Angiogenesis Inhibitors automatically
Every clearance here is in the API, with alerts when new ones post.